PMID- 18422971
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20240103
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 52
IP  - 7
DP  - 2008 Jun
TI  - Assessment of a HER2 scoring system for gastric cancer: results from a validation 
      study.
PG  - 797-805
LID - 10.1111/j.1365-2559.2008.03028.x [doi]
AB  - AIMS: Human epidermal growth factor receptor 2 (HER2) 
      overexpression/amplification is implicated in the development of various solid 
      tumour types. Validated methods and scoring systems for evaluating HER2 status 
      exist in breast cancer, but not in gastric cancer. The aim was to establish a 
      HER2 scoring system for gastric cancer to identify suitable patients for 
      enrollment in a trial of trastuzumab (Herceptin) in advanced metastatic gastric 
      cancer. METHODS AND RESULTS: Formalin-fixed paraffin-embedded gastric cancer 
      samples were tested for HER2 status using the fluorescence in situ hybridization 
      (FISH) pharmDxt kit (Dako Denmark A/S). Immunohistochemistry (IHC) was performed 
      using the HercepTest (Dako). Concordance between FISH and IHC was 93.5% in 168 
      evaluable samples. Eleven samples were scored as FISH+ but IHC- or equivocal. 
      CONCLUSIONS: IHC/FISH discrepancies were attributed to basolateral membranous 
      immunoreactivity of glandular cells resulting in incomplete membranous reactivity 
      and/or a higher rate of tumour heterogeneity in gastric cancer compared with 
      breast cancer. With modifications to the IHC scoring system, the HercepTest is 
      considered valid for the identification of HER2+ gastric tumours for this 
      clinical trial. Correlation of HER2 scores with clinical outcomes will be needed 
      to determine which patients might benefit from trastuzumab therapy.
FAU - Hofmann, M
AU  - Hofmann M
AD  - Institute of Pathology, Klinikum Kassel, Kassel, Germany.
FAU - Stoss, O
AU  - Stoss O
FAU - Shi, D
AU  - Shi D
FAU - Buttner, R
AU  - Buttner R
FAU - van de Vijver, M
AU  - van de Vijver M
FAU - Kim, W
AU  - Kim W
FAU - Ochiai, A
AU  - Ochiai A
FAU - Ruschoff, J
AU  - Ruschoff J
FAU - Henkel, T
AU  - Henkel T
LA  - eng
PT  - Comparative Study
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20080418
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/classification/*metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Consensus
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Receptor, ErbB-2/*metabolism
MH  - Reproducibility of Results
MH  - Stomach Neoplasms/classification/*metabolism
RF  - 40
EDAT- 2008/04/22 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/04/22 09:00
PHST- 2008/04/22 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/04/22 09:00 [entrez]
AID - HIS3028 [pii]
AID - 10.1111/j.1365-2559.2008.03028.x [doi]
PST - ppublish
SO  - Histopathology. 2008 Jun;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. 
      Epub 2008 Apr 18.